Digital tests could detect Alzheimer far earlier

In recent years, blood biomarkers (measurable proteins in blood that signal Alzheimer’s-related changes in the brain) have advanced significantly. They can detect pathological changes long before any symptoms appear. Yet clinical pathways still wait for late-stage cognitive impairment before acting. That is the core problem the authors describe in Nature Aging.

Traditional cognitive tests were designed to measure advanced loss. They miss the subtle early changes in memory and attention that occur years before a formal diagnosis. Digital tasks designed specifically to challenge the brain systems that Alzheimer’s affects first can detect those early changes.

Which brain systems are first at risk

The authors outline which cognitive systems are affected earliest: spatial memory, navigation, and the ability to encode new information, all of which depend heavily on the hippocampus. Digital tasks that specifically target those systems are more sensitive to early Alzheimer’s-related decline than broad screening tests.

Combined with blood biomarkers, targeted digital assessments could provide stronger predictions of who is at risk for decline. The authors call for integrating these tools into clinical pathways alongside plasma biomarkers, not as a replacement, but as a complement.

Why this matters now

With disease-modifying treatments for Alzheimer’s now emerging, early detection is increasingly consequential. The evidence suggests these treatments work best when started early, before widespread damage has occurred. A diagnostic system that waits for late symptoms delays the point at which treatment could be most effective.

This commentary presents no new trial data. It synthesizes the current state of the field. The argument is clear: cognitive diagnostics must be updated at the same pace as molecular diagnostics. Right now, the two are out of step.

Read the original article